BIEL: Interim Results Are In, ActiPatch vs Extra Stregnth Tylenol

BIEL.pk: BioElectronics Corp. issued a press release on Monday announcing that the preliminary results are in for an ongoing comparison study measuring the effectiveness between ActiPatch and Extra Strength Tylenol in treating exercise-induced muscle pain.

The early results, according to the press release, showed that ActiPatch had "superior efficacy" to Extra Strength Tylenol. The full results should be released in November.

The BIEL stock price remained relatively unchanged with the announcement, but the data gives investors a good indication that ActiPatch may receive favorable review from the US FDA if the end-of-study results are as convincing as the preliminary results.

As the general public, along with regulatory agencies, begin to look for alternatives in the market to Acetaminophen and Ibuprofen due to health concerns, BioElectronics is in a prime position to take advantage of the shift in market (and medical) trend.

With BIEL trading in the somewhat stable seven to eight cents range as investors await the pending FDA decisions, I like the buying opportunity that presents itself on the dips and I think that in the mid to long term, a buy for under ten cents is going to end up looking like a steal.

I've made no secret of the fact that I think that BioDelivery's products to treat various indications of pain and swelling has the potential to become a world-wide alternative to Tylenol and Ibuprofen and I am investing accordingly.

Aside from the upcoming FDA decisions, investors should gain a little bit more confidence in the business side of things since the company's stock symbol is now listed on the pink sheets without the dreaded 'Caveat Emptor' rating.

The interim news on the comparison study is encouraging and investors in the company will be anxiously awaiting the full results come November.

For now, it's a waiting game for the pending FDA decisions.

Disclosure: VFC is long BIEL.